Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Immunol. 2019 Jun 12;203(3):718–724. doi: 10.4049/jimmunol.1900271

Fig 1. TRAILshort Knockdown Enhances TRAIL Sensitivity and Alters T Cell Viability Following Acute HIV Infection in vitro.

Fig 1.

(A) Jurkat T cells were transduced with lentiviral vectors containing control or TRAILshort-targeting shRNA, and assessed for expression of TRAIL and TRAILshort by western blot. (B) Surface expression of full-length TRAIL, TRAIL-R1 and TRAIL-R2 was assessed by flow cytometry. Shaded area indicates isotype control staining. (C) Control LV or TRAILshort KD Jurkat T cells were treated with control or skTRAIL and assessed for apoptosis by TUNEL staining. (D) Transduced cells treated as in (C) assessed for ATP content in the presence of increasing concentrations of skTRAIL. (E) Transduced cells were assessed for ATP content in the presence of increasing concentrations of hydrogen peroxide. (F) Control LV cells or TRAILshort KD cells were mixed 50:50 with parental Jurkat cells, infected with HIV-IIIB, and assessed for survival over time by flow cytometry. (G) Control LV cells or TRAILshort KD cells were infected with a low MOI of HIV-IIIB and viability assessed over time by LIVE/Dead staining flow cytometry. (H) Culture supernatant HIV-1 p24 was measured from cells treated as in (G). Data represent mean values for 2 (panels C, D, and E) or 3 (F and G) independent experiments. P values were determined by linear regression.